Clinical observation of docetaxel combined with cisplatin in treatment of advanced esophageal cancer with synchronous radiotherapy

Wei-Hua WANG,Qian CHEN,Dao-wen JIANG

DOI: https://doi.org/10.7501/j.issn.1674-5515.2014.11.019

2014-01-01

Abstract:Objective To explore the clinical effect and safety of docetaxel combined with cisplatin in treatment of advanced esophageal cancer with synchronous radiotherapy. Methods Patients with advanced esophageal cancer who came to the Central Hospital of Minhang District in Shanghai from March 2009 to March 2011 (112 cases) were randomly divided into control (56 cases) and treatment (56 cases) groups. Patients in two groups were given radiotherapy. The patients in the control group were iv administered with Cisplatin Injection (25 mg/m2) for 1— 3 d and Fluorouracil Injection (500 mg/m2) for 1— 5 d on the basis of radiotherapy. The patients in the control group were iv administered with Docetaxel Injection (20 mg/m2) for 1— 3 d and Cisplatin Injection (25 mg/m2) for 1— 3 d. Two treatment options started since the first day of radiotherapy, and continuous treatment of 21 d was as one course. Short-term clinical effect was evaluated, while followed up for 24— 48 months, and the survival rate and progression-free survival rate were calculated. Results The efficacies in the treatment and control groups were 91.07% and 80.36%, respectively, and there were differences between the two groups (P< 0.01). Survival rates of 2, 3, 4 years in the treatment group were obviously higher than those of the control group (P < 0.05). The occurrence of Ⅲ - Ⅳ nausea, vomiting, radioactive esophagitis, and stomatitis in the treatment group was significantly lower than that in the control group, and there were differences between the two groups (P < 0.05). Conclusion Docetaxel combined with cisplatin has good clinical effect in treatment of advanced esophageal cancer with synchronous radiotherapy, and also has a good effect for long-term survival, which is worthy of clinical application.